Fosamprenavir Calcium

Phase 2Small molecule

Fosamprenavir Calcium is one of 12 small molecule programs targeting Laryngopharyngeal Reflux. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Laryngopharyngeal RefluxRecruiting

Laryngopharyngeal RefluxPhase 2

Recruiting

Competition

Competitive Landscape

11 competitors in Laryngopharyngeal Reflux

#DrugCompanyPhaseTrials

Prevacid

Takeda

Approved

—2

Protonix

WWyeth-Lederle Vaccines

Approved

2 3

Nexium

DDexcel Pharma Technologies Ltd.

Approved

2 4

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

1 5

Zantac 150

CChattem

Approved

1 6

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

1 7

Motilitone

DDong-A Pharmaceutical Co., Ltd.

Phase 3

1 8

Sodium Alginate

KKyungpook National University Hospital

Phase 3

1 9

Aciphex

Mylan Pharmaceuticals Inc

Phase 3

1 10

Dexilant

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Laryngopharyngeal Reflux

NCT04383262

Q1 2029

Phase 2Not yet recruiting

Refractory Gastroesophageal Reflux Disease

NCT06704100

Clinical

Trials by Indication[1]

Refractory Gastroesophageal Reflux Disease1 trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Trial of Fosamprenavir-Sodium Alginate Administered Orally for 8 Weeks to Patients With Proton Pump Inhibitor Refractory Gastroesophageal Reflux Disease

Not yet recruiting·MMedical College of Wisconsin·Phase 2·NCT06704100·60 enrolled

Laryngopharyngeal Reflux1 trial

A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of Oral Fosamprenavir for Laryngopharyngeal Reflux

Recruiting·MMedical College of Wisconsin·Phase 2·NCT04383262·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Fosamprenavir Calcium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fosamprenavir Calcium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fosamprenavir Calcium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical College of Wisconsin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMedical College of Wisconsin

Fosamprenavir Calcium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Trials by Indication[1]

Refractory Gastroesophageal Reflux Disease1 trial

Laryngopharyngeal Reflux1 trial

References

Drug Info

Quick Facts

Related News